Martin Fruh - Kantonsspital St. Gallen

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 140 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy

crossref（2024）

Cited0Views0Bibtex

Autoimmunity Against Surfactant Protein B is Associated with Pneumonitis During Checkpoint Blockade

American journal of respiratory and critical care medicineno. 7 (2024): 919-930

Cited0Views0WOSBibtex

MA11.09 SAKK 16/18: Neoadjuvant Chemotherapy, Durvalumab and Immune-Modulatory RT in Stage III(N2) NSCLC. Surgical Interim Analysis

Journal of Thoracic Oncologyno. 11 (2023): S139-S140

Cited0Views0Bibtex

Neoadjuvant Treatment Does Not Influence PD-L1 Expression in Stage III Non-Small-cell Lung Cancer: a Retrospective Analysis of Tumor Samples from the Trials SAKK 16/96, 16/00, 16/01, and 16/14

D. Konig,S. Savic Prince,S. Hayoz,P. Zens,S. Berezowska,W. Jochum, E. Stauffer, V. Braunersreuther, B. Trachsel,S. Thierstein,M. Mark,S. Schmid,I. Opitz,M. Guckenberger,M. Fruh,D. C. Betticher,H. -B. Ris,R. Stupp,S. I. Rothschild,L. Bubendorf,M. Pless

ESMO openno. 4 (2023): 101595-101595

Cited0Views0WOSBibtex

SAKK 16/18: Neoadjuvant Chemotherapy, Durvalumab and Immune-Modulatory RT in Stage III(N2) NSCLC. Surgical Interim Analysis

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S139-S140

Cited0Views0Bibtex

Pembrolizumab vs placebo for early-stage non.small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study

Kersti Oselin,Byoung Yong Shim,Morihito Okada,Maciej Bryl,Laura Bonanno,Guzin Demirag,Ida Colantonio,Martin Kimmich,Urska Janzic,Johan F. Vansteenkiste,Reyes Bernabe Caro,Amina Scherz,Alessandra Curioni-Fontecedro,Martin Fruh,Mira Wollner, Jing Yang, Nazly Shariati,Sandrine Marreaud,Solange Peters,Mary Er O'Brien

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 8520-8520

Cited0Views0Bibtex

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

Med (New York, N.Y.)no. 2 (2023): 113-129.e7

Cited20Views0WOSBibtex

Combined chemo-immunotherapy as first-line treatment in patients with advanced/metastatic small cell lung cancer ("extensive disease") - a real-world, multicenter analysis

N. Zellweger,S. Schmid,M. Bertschinger,C. Waibel,F. Cerciello,P. Froesch,M. Mark,A. Bettini, P. Hauptle,V Blum, T. Litke,F. Helfenstein,M. Fruh,L. Mauti,S. Rothschild

ONCOLOGY RESEARCH AND TREATMENTno. SUPPL 2 (2022)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn